Plaque Psoriasis

The FDA has approved Selarsdi as a biosimilar to Stelara for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis, Teva Pharmaceuticals and Alvotech announced in a press release.

Once-daily roflumilast cream 0.3% was well tolerated and efficacious in the long-term treatment of patients with plaque psoriasis, suggesting it is suitable for chronic treatment, according to a study.

In this Healio exclusive video, Steven R. Feldman, MD, PhD, discussed study results presented at the American Academy of Dermatology Annual Meeting examining bimekizumab in the treatment of psoriasis.

In this Healio exclusive video, Steven R. Feldman, MD, PhD, discussed psoriasis research from the phase 2 STRIDE study presented at the American Academy of Dermatology Annual Meeting.

In this Healio exclusive video, Steven R. Feldman, MD, PhD, discussed psoriasis research from the phase 2 KNOCKOUT study presented at the American Academy of Dermatology Annual Meeting.

In this Healio exclusive video, Steven R. Feldman, MD, PhD, discussed psoriasis research from the American Academy of Dermatology Annual Meeting examining the LITE study in plaque-type psoriasis.

SAN DIEGO — Patients treated with JNJ-2113 for moderate to severe plaque psoriasis maintained skin clearance up to 1 year, according to a late-breaking presentation at the 2024 American Academy of Dermatology Annual Meeting.

Arcutis has entered into a licensing agreement with Sato Pharmaceutical Co. Ltd. to develop, manufacture and commercialize topical roflumilast in Japan for the treatment of multiple skin conditions, according to a company press release.

The efficacy of tapinarof cream 1% has validated the aryl hydrocarbon receptor as a therapeutic target for the treatment of atopic dermatitis, according to a study.

Using the efficiency frontier approach to negotiate prices for plaque psoriasis biologics may lead to substantial price reductions that better align with clinical benefits in the U.S., according to a study.